BioSpace News Archive

Kerecis®, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, is donating its Kerecis Omega3 Burn product for burn victims of the fires in California, Oregon and Washington.

HiFiBiO Therapeutics , a clinical-stage multinational biotherapeutics company focused on the development of novel antibodies in immunomodulation, today announced a partnership agreement with South Korea-based ABL Bio to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients. The two companies will join forces to drive the development of t

Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million aggregate principal amount of senior notes due 2029. Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375% senior unsecu

A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the H.C. Wainwright 22nd Annual Global Investment Conference

Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com

Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma (DIPG), a lethal brain tumor occurring in the pontine region of the brain. DIPG accounts for approximately 10 to 15 percent of all cases of brain tumo

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today provided an update on the upcoming special meeting of stockholders (the “Meeting”) in response to recent stockholder inquiries regarding the number of meeting adjournments. The sole purpose of the Meeting is to seek approval of a proposal to

Cancer patient advocates and medical professionals in more than 20 countries are planning activities for World Gynecologic Oncology Day (World GO Day) this month. A project of the European Society of Gynaecological Oncology (ESGO) and the E

Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021